Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 9Phase 1 7Phase 3 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 95Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 21Squamous Cell Carcinoma of Head and Neck 19Melanoma 19Triple Negative Breast Neoplasms 14Stomach Neoplasms 13Breast Neoplasms 13Neoplasm Metastasis 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Neoplasms 9Carcinoma 9Carcinoma, Transitional Cell 7Carcinoma, Hepatocellular 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Esophageal Neoplasms 4Cholangiocarcinoma 4Thoracic Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lung Diseases 3

Interventions

pembrolizumab 2cemiplimab 1avelumab 1atezolizumab 1Saline Solution 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Merkel Cell × pembrolizumab × Clear all
NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03783078 2025-05-28

KEYNOTE-913

Merck Sharp & Dohme LLC

Phase 3 Completed
55 enrolled 14 charts
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡